AstraZeneca's anti-CTLA4 antibody tremelimumab is moving closer to what once looked like an extremely unlikely regulatory approval, after a string of negative trial results. The drugmaker said ...

Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136] Draft guidance Technology appraisal guidance 3 March ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable ...

Tarlatamab for previously treated advanced small-cell lung cancer [ID6364] Draft guidance Technology appraisal guidance 18 February 2025 Durvalumab with tremelimumab for untreated advanced or ...

4 The nice thing about this trial is you continued on the chemotherapy for up to 4 cycles with the durvalumab [Imfinzi] and tremelimumab [Imjudo] every 3 weeks, but then the CTLA-4 inhibitor ...

Accessed February 2025. 9. Senan S, et al. ADRIATIC: A phase III trial of durvalumab ± tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer.

Tremelimumab is under clinical development by AstraZeneca and currently in Phase III for Urethral Cancer. According to GlobalData, Phase III drugs for Urethral Cancer does not have sufficient ...